Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2302542 | 0.94 | SIRT1 (0.33) | KDM4EPOLBL3MBTL1MCL1 | |
| Piperazine SCHEMBL2427260 | 0.85 | TSHR (0.36) | — | |
| Piperidine SCHEMBL2428246 | 0.82 | TSHR (0.34) | ALDH1A1 | |
| SCHEMBL4590212 | 0.82 | SIRT1 (0.35) | KDM4EPOLBL3MBTL1MCL1 | |
| SCHEMBL27766757 | 0.79 | CES2 (0.37) | MCL1MAPK1KMT2AALDH1A1 | |
| SCHEMBL2305287 | 0.77 | MAPK1 (0.36) | KDM4EPOLBMCL1MAPK1KMT2A | |
| SCHEMBL3553694 | 0.71 | MCL1 (0.60) | KDM4EPOLBL3MBTL1MCL1MAPK1 | |
| SCHEMBL15414620 | 0.71 | KDM4E (0.43) | KDM4EPOLBL3MBTL1MCL1MAPK1 | |
| SCHEMBL612494 | 0.71 | MCL1 (0.60) | KDM4EPOLBL3MBTL1MCL1MAPK1 | |
| SCHEMBL29978857 | 0.71 | KDM4E (0.39) | KDM4EPOLBL3MBTL1MCL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350311-B1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | MADRIGAL PHARMACEUTICALS INC (US) | 2013-12-25 | — | — | EP | claimed |
| US-8324385-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | claimed |
| CN-102203280-A | Diacylglycerol acyltransferase inhibitors | VIA PHARMACEUTICALS INC | 2011-09-28 | — | — | CN | claimed |
| EP-2350311-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Via Pharmaceuticals, Inc. (US) | 2011-08-03 | — | — | EP | claimed |
| WO-2010056506-A1 | DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | claimed |
| US-20100113782-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2010-05-06 | — | — | US | claimed |
| EP-0337348-A2 | Amides of cyclomethylen-1,2-bicarboxylic acids having therapeutical activity, processes for their preparation and pharmaceutical compositions containing them | Laboratori Guidotti S.p.A. (IT) | 1989-10-18 | — | — | EP | claimed |
| US-10106502-B2 | Direct inhibitors of Keap1-Nrf2 interaction as antioxidant inflammation modulators | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180148408-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2018-05-31 | — | — | US | disclosed |
| US-20140256767-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | THE BROAD INSTITUTE, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| WO-2013067036-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-05-10 | — | — | WO | disclosed |
| CN-102203280-A | Diacylglycerol acyltransferase inhibitors | VIA PHARMACEUTICALS INC | 2011-09-28 | — | — | CN | disclosed |
| EP-2350311-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Via Pharmaceuticals, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010056506-A1 | DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148408-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | KEAP1, NFE2L2, HMOX1 | KDM4E 3430/4885POLB 3040/4885L3MBTL1 2057/4885 |
| US-20100113782-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, MOGAT2 | KDM4E 3683/4885POLB 3823/4885L3MBTL1 615/4885 |
| US-10106502-B2 | Direct inhibitors of Keap1-Nrf2 interaction as antioxidant inflammation modulators | KEAP1, NFE2L2, HMOX1 | KDM4E 3430/4885POLB 3040/4885L3MBTL1 2057/4885 |
| US-20140256767-A1 | DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS | KEAP1, NFE2L2, HMOX1 | KDM4E 3430/4885POLB 3040/4885L3MBTL1 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.